1. Home
  2. TORO vs SPRO Comparison

TORO vs SPRO Comparison

Compare TORO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

HOLD

Current Price

$5.07

Market Cap

174.5M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.19

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TORO
SPRO
Founded
2022
2013
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.5M
156.3M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
TORO
SPRO
Price
$5.07
$1.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.2K
1.5M
Earning Date
04-15-2026
05-13-2026
Dividend Yield
36.86%
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$2.64
$1.10
52 Week High
$8.50
$3.08

Technical Indicators

Market Signals
Indicator
TORO
SPRO
Relative Strength Index (RSI) 56.96 18.94
Support Level $4.87 N/A
Resistance Level $5.25 $2.44
Average True Range (ATR) 0.16 0.16
MACD 0.03 -0.07
Stochastic Oscillator 84.40 6.19

Price Performance

Historical Comparison
TORO
SPRO

About TORO Toro Corp.

Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: